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IMPORTANCE Schizophrenia is a highly heritable, polygenic condition characterized by a
relatively diverse phenotype and frequent comorbid conditions, such as anxiety and
depression. At present, limited evidence explains how genetic risk for schizophrenia is
manifest in the general population.
OBJECTIVE To investigate the extent to which genetic risk for schizophrenia is associated
with different phenotypes during adolescence in a population-based birth cohort.
DESIGN, SETTING, AND PARTICIPANTS This cohort study used data from the Avon Longitudinal
Study of Parents and Children (ALSPAC). Of 14 062 children in the birth cohort, genetic data
were available for 9912 adolescents. Data were collected periodically from September 6,
1990, and collection is ongoing. Data were analyzed fromMarch 4 to August 13, 2015.
EXPOSURES Polygenic risk scores (PRSs) for schizophrenia generated for individuals in the
ALSPAC cohort using results of the second Psychiatric Genomics Consortium Schizophrenia
genome-wide association study as a training set.
MAIN OUTCOMES ANDMEASURES Logistic regressionwas used to assess associations
between the schizophrenia PRS and (1) psychotic experiences (Psychosis-Like Symptom
Interview at 12 and 18 years of age), (2) negative symptoms (Community Assessment of
Psychic Experiences at 16.5 years of age), (3) depressive disorder (Development and
Well-Being Assessment at 15.5 years of age), and (4) anxiety disorder (Development and
Well-Being Assessment at 15.5 years of age) in adolescence.
RESULTS Of the 8230 ALSPAC participants whose genetic data passed quality control checks
(51.2%male, 48.8% female), 3676 to 5444 participated in assessments from 12 to 18 years of
age. The PRSs created using single-nucleotide polymorphisms with a training-set P  .05
threshold were associated with negative symptoms (odds ratio [OR] per SD increase in PRS,
1.21; 95% CI, 1.08-1.36; R2 = 0.007) and anxiety disorder (OR per SD increase in PRS, 1.17; 95%
CI, 1.06- 1.29; R2 = 0.005). No evidence was found of an association between schizophrenia
PRS and psychotic experiences (OR per SD increase in PRS, 1.08; 95% CI, 0.98-1.19;
R2 = 0.001) or depressive disorder (OR per SD increase in PRS, 1.02; 95% CI, 0.91-1.13;
R2 = 0.00005). Results were mostly consistent across different training-set P value
thresholds and using different cutoffs andmeasures of the psychopathological outcomes.
CONCLUSIONS AND RELEVANCE This study demonstrates polygenic overlaps between
common genetic polymorphisms associated with schizophrenia and negative symptoms and
anxiety disorder but not with psychotic experiences or depression. Because the genetic risk
for schizophrenia appears to bemanifest as anxiety and negative symptoms during
adolescence, a greater focus on these phenotypes rather than on psychotic experiences
might be required for prediction of transition in at-risk samples.
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S chizophrenia has a heritability of approximately 80%,and genome-wide association studies (GWASs) indi-cate that multiple independent loci contribute to its
etiology.1 The importance of studying the phenotypic mani-
festations of increased genetic liability for schizophrenia
has been long recognized and originally involved small
samples of individuals at high risk as indexed by having a
family history.2 Genetic advances now provide the opportu-
nity to extend the power and generalizability of high-risk
studies into the general population by examining individu-
als according to genetic risk. Although individual loci have
small effects on risk, multiple-loci approaches show that,
cumulatively, alleles on current GWAS platforms explain
one-half to one-third of the genetic risk for schizophrenia.3,4
Information from even moderately associated alleles can be
collapsed into a single polygenic risk score (PRS) that can be
used to explore shared genetic effects with other disorders
and to examine how genetic risk is manifest early during
development.5
Schizophrenia is defined by psychotic experiences (hal-
lucinations, delusions, and thought disorder) and negative
symptoms (eg, blunted affect and apathy), although cogni-
tive deficits are also common as is comorbiditywith other di-
agnoses, particularly affective and anxiety disorders.6 Longi-
tudinal studies show that anxiety, depression, and cognitive
deficits often predate schizophrenia,7-11 indicating that these
phenotypes might represent early expression of genetic risk
for schizophrenia. Although genetic overlap across psychiat-
ric disorders is common,12-15 knowledge of howgenetic risk is
expressed at different stages of the life course could foster un-
derstanding of the etiologic mechanisms and risk prediction
and inform targeted interventions.
Three previous studies16-18 have used a schizophrenia
PRS generated from a GWAS training set that captured
approximately 3% of the proportion of risk variance4 to
examine associations with symptoms that characterize
schizophrenia. In the first study,16 the schizophrenia PRS
was not associated with symptom dimensions characteristic
of the disorder in cases with schizophrenia or control indi-
viduals (while associations within the whole sample were
attributed to confounding by case-control status). Similarly,
another study17 reported no association with positive symp-
tom, cognitive, and negative symptom dimensions in a gen-
eral population sample of adolescents. Finally, the third
study18 found no strong evidence that the schizophrenia
PRS was associated with psychotic experiences at 12 years of
age within the population-based Avon Longitudinal Study
of Parents and Children (ALSPAC) birth cohort. Subse-
quently, a larger GWAS1 has been completed that explains a
much greater proportion of risk variance, thus providing
greater power to examine how genetic risk is manifest dur-
ing development.19 We aimed to examine the psychopatho-
logical features associated with the early expression of
genetic risk for schizophrenia and, more specifically,
whether a schizophrenia PRS derived from the most recent
GWAS is associated with (1) psychotic experiences, (2) nega-
tive symptoms, (3) anxiety disorders, or (4) depression dur-
ing adolescence in a large population-based sample.
Methods
Participants
The sample consisted of young individuals within the
ALSPAC cohort. The initial cohort consisted of 14062 chil-
dren born to women residing in the former Avon Health
Authority area with an expected delivery date from April 1,
1991, to December 31, 1992 (http://www.bristol.ac.uk
/alspac/; all available data are given at http://www.bristol
.ac.uk/alspac/researchers/access/).20,21 Data were collected
periodically from September 6, 1990, and collection is ongo-
ing. Ethical approval for the study was obtained from the
ALSPAC Law and Ethics Committee and the local research
ethics committees (listed at http://www.bristol.ac.uk/alspac
/researchers/research-ethics/). All participants provided
written informed consent.
Genetic Data
Genetic data were acquired from 9912 participants using a
genome-wide single-nucleotide polymorphism (SNP) geno-
typing platform (HumanHap550-Quad; Illumina). After qual-
ity control assessment, imputation, and restriction to 1 ado-
lescent per family, genetic data were available for 8230
individuals (more detail is found in the eMethods in the
Supplement).
Measures
Psychotic Experiences
The semistructured Psychosis-Like Symptom Interview22,23
was used to assess psychotic experiences (hallucinations,
delusions, or experiences of thought interference) at ages 12
and 18 years. To maximize the numbers within our sample,
individualsweredeemedtohaveapsychoticexperience if rated
as having 1 or more definite psychotic experiences at 12 or 18
years of age comparedwith no experiences or suspected psy-
chotic experiences only at 12 or 18 years of age. More details
onthePsychosis-LikeSymptomInterviewandontheotherout-
come measures used in this study are given in the eMethods
in the Supplement.
Negative Symptoms
Negative symptoms were assessed using 10 questions based
on items from the Community Assessment of Psychic Expe-
riences self-report questionnaire24 at 16.5 years of age
(eMethods and eTable 1 in the Supplement). The questions
measurenegative symptoms, suchasapathy, anergia, andaso-
ciality. Each item was rated on a 4-point scale (0 indicates
never; 1, sometimes; 2, often; and3, always). A total scorewas
constructed based on the sum of responses (minimum score,
0;maximumscore, 30). A binary variablewas created using a
total score of 14 as a cutoff thatwas chosen to define approxi-
mately the top decile (9.18%) of the sample.
Depressive and Anxiety Disorders
Depressive and anxiety disorder outcomeswerederived from
the semistructured Development and Well-Being Assess-
ment interviewat 15.5 years of age. The interview is a valid in-
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strument in community and clinical samples.25 International
Statistical Classification of Diseases and Related Health Prob-
lems, Tenth Revision and DSM-IV diagnoses of depressive or
any anxiety disorder were generated using a computerized
diagnostic algorithm that predicts the likelihood of a clinical
diagnostic rating (more information is available at
http://www.DAWBA.com).26
Wedefined individuals as having adepressive disorder or
an anxiety disorder if they were categorized in the Develop-
mentandWell-BeingAssessmentbandpredictingat leasta 15%
probability of clinical diagnosis, a cutoff selected todefine the
approximate topdeciles of the sample.We conducted a series
of sensitivity analyses using different phenotype score cut-
offs to define binary outcomes and using different measures
whereavailable to test therobustnessofour findings (eMethods
in the Supplement).
Polygenic Risk Score
Constructionof thePRS follows themethodsdescribedby the
International Schizophrenia Consortium.4 The PRS was con-
structed using results from the second Psychiatric Genomics
Consortium (PGC) schizophrenia GWAS (eMethods in the
Supplement).1 Polygenic scores were calculated for each
ALSPAC individual using the PLINK (version 1.07) score
command.27 Scores were created by summing the number of
riskallelespresent foreachSNP(0, 1,or2)weightedbythe loga-
rithm of its odds ratio (OR) for schizophrenia from the PGC.
Our primary analysis used scores generated from a list of
SNPswith aGWAS training-setP ≤. 05 threshold,which is the
threshold thatmaximally captures schizophrenia liability.1 Be-
cause the composition of a PRS is a balance between true and
null effects,28 scores generated using lists of SNPs meeting a
series of P value thresholds and using all independent SNPs
meeting genome-wide significance as reported by the PGC
schizophrenia GWAS1 were used in sensitivity analyses.
Statistical Analysis
Datawere analyzed fromMarch4 toAugust 13, 2015.Weused
logistic regression to test the association between outcomes
and the schizophrenia PRS. Results are presented as ORs and
95%CIs per SD increase in PRS. NagelkerkeR2 values are also
presented as a measure of variance explained. Nonlinear as-
sociations between the PRS and outcomeswere examined by
inclusion of quadratic terms. We examined whether associa-
tionswith our outcomeswere independent by inclusion of all
phenotypeswithin amultivariablemodel. To correct formul-
tiple testing arising from using different P value thresholds
within our sensitivity analyses, we computed permutation-
adjusted P values (eMethods in the Supplement).
To test whether the effect size of the schizophrenia PRS
was the same or different across phenotypes, we used bivar-
iate probit regression to model pairs of outcomes jointly. We
tested equality of regression parameters expressing the ef-
fect of the schizophrenia PRS (threshold P = .05) on each out-
come using a likelihood ratio test to compare amodel that al-
lowseffectestimates todifferwithamodelwherethePRSeffect
was constrained to be equal for both outcomes.29,30 All sta-
tistical analyses were performed using STATA statistical soft-
ware (version 13; StataCorp LP).
Results
Associations Between Schizophrenia PRS
and Psychopathological Outcomes
Thenumbersof individualswhoparticipated in thePsychosis-
Like Symptom Interview at 12 and 18 years of age or com-
pleted questions relating to negative symptoms at 16.5 years
ofageanddepressionandanxietyat 15.5yearsofageareshown
in Table 1. Of 8230 ALSPAC adolescents whose genetic data
passed quality control checks (51.2% male and 48.8% fe-
male), 3676 to 5444 participated in assessments from 12 to 18
years of age.
We found no strong evidence that individuals who had a
higher PRS, and thus increased genetic risk for schizophre-
nia, had an increased risk for developing psychotic experi-
ences (ORper SD increase in PRS, 1.08; 95%CI, 0.98-1.19; per-
mutation-adjusted P = .14;R2 = 0.001) (Figure, A, and eTable
2 in the Supplement).
We observed strong evidence of an association between
the schizophrenia PRS and negative symptoms at 16.5 years
of age (OR, 1.21; 95% CI, 1.08-1.36; permutation-adjusted
Table 1. IndividualsWith OutcomeMeasurea
Age, y
Data
Source
Outcome
Measure
Binary Outcome
Measure Type
All Participants Genotyped Participants
No. Outcome, No. (%) No. Outcome, No. (%)
12 PLIKSI Psychotic experiences Yes or no 6792 383 (5.64) 5103 280 (5.49)
18 PLIKSI Psychotic experiences Yes or no 4718 229 (4.85) 3486 168 (4.82)
12 and 18b PLIKSI Psychotic experiences Yes or no 7452 575 (7.72) 5444 419 (7.70)
16.5 CAPE Negative symptoms Score <14 or ≥14c 5095 467 (9.17) 3673 337 (9.18)
15.5 DAWBAd Depression <15% or ≥15% likelihood 5365 498 (9.28) 4106 373 (9.08)
15.5 DAWBAd Anxiety <15% or ≥15% likelihood 5367 596 (11.10) 4107 444 (10.81)
Abbreviations: CAPE, Community Assessment of Psychic Experiences;
DAWBA, Development andWell-Being Assessment; PLIKSI, Psychosis-Like
Symptom Interview.
a Includes psychotic experiences, negative symptoms, depression, and anxiety.
b Indicates individuals who completed at least 1 interview session at 12 and/or 18
years of age.
c Total scores range from0 to 30, with higher scores indicating worse
symptoms.
dAn individual within the 15% band category has a 15% likelihood of having a
depressive or anxiety disorder. Higher percentage categories indicate a higher
chance of having a depressive or anxiety disorder.
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P = .001; R2 = 0.007) (Figure, B, and eTable 2 in the Supple-
ment).Wealsoobservedstrongevidence that individualswith
a higher schizophrenia PRSwere at an increased risk for anxi-
ety disorder at 15.5 years of age (OR per SD increase in poly-
Figure. Associations Between Polygenic Risk Scores (PRSs) for Schizophrenia and Phenotypes
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Odds ratios (ORs) per SD change in
PRS for schizophrenia are shown
(data markers), with upper and lower
error bars indicating 95% CIs. The
ORs are shown for a range of PRSs
generated using lists of
single-nucleotide polymorphisms
(SNPs) meeting a series of P value
thresholds. The bars indicate the
log10 times the number of SNPs used
to create the PRSs. A genome-wide
significant (threshold P = 5 × 10−8)
PRS was created from 111
genome-wide significant
schizophrenia SNPs as reported by
the second Psychiatric Genomics
Consortium.1 Red lines indicate the
null value.
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genic score, 1.17; 95% CI, 1.06-1.29; permutation-adjusted
P = .002; R2 = 0.005) (Figure, D, and eTable 2 in the Supple-
ment). We found no strong evidence of an association be-
tween thePRSanddepressivedisorder at 15.5 years of age (OR
per SD increase inpolygenic score, 1.02; 95%CI,0.91-1.13; per-
mutation-adjusted P = .77; R2 = 0.00005) (Figure, C, and
eTable 2 in the Supplement).
We found no strong evidence to support nonlinear ef-
fects ofpolygenic riskonanyof thephenotypesexamined.Re-
sults per decile of PRS for a training-set threshold of P = .05
arepresented ineTable3 in theSupplement.Associationswith
negative symptoms and anxiety disorder were independent
andpersistedwhen testing all phenotypeswithin amultivari-
able model (eTables 4 to 7 in the Supplement).
Common and Specific AssociationsWith Schizophrenia PRS
Tetrachoric correlationsbetweeneachpsychopathologicalout-
come are shown in eTable 8 in the Supplement. The results of
the bivariate analyses examining whether the schizophrenia
PRS(thresholdP = .05)effectsizesaresimilarordifferentacross
phenotypesare summarized inTable2.Weobservedsomeevi-
dence that the strong associations between the schizophre-
niaPRSandnegative symptomsandanxiety aredifferent from
theassociationbetween thePRSanddepression (bothP = .02),
with weaker evidence that they are different from the asso-
ciations of the PRS with psychotic experiences (P = .14 and
P = .11, respectively).We foundnostrongevidence that the as-
sociation between the PRS effect and negative symptoms dif-
fered from that for anxiety (P = .92).
Sensitivity Analyses
Our resultswereunchangedwhenweuseddifferent cutoff val-
uesordifferentmeasurementtoolstoassessouroutcomes(eFig-
ures 1-5 in theSupplement),whenweadjusted forparental self-
reported history of schizophrenia or depression, or when we
excludedindividualswithapsychoticdisorderat 18yearsofage.
Results were also consistent across all training-set P value
thresholds for almost all outcomes. The exception was psy-
chotic experiences, forwhichwe foundweakevidence that in-
creasedgenetic riskwasassociatedwithadecreasedriskofpsy-
chotic experiences at lower training-set P value thresholds
(threshold P ≤ 1 × 10−7; OR per SD increase in polygenic score,
0.90; 95% CI, 0.81-0.99; permutation-adjusted P = .04;
R2 = 0.002) (Figure, A, and eTable 2 in the Supplement).
Discussion
In this study, we examined how an increased genetic risk for
schizophrenia is manifest phenotypically during adoles-
cence in the general population. We found no strong evi-
dence of an association with the occurrence of psychotic ex-
periences or depressive disorder. However, we found strong
evidence that negative symptoms and anxiety disorderswere
more common in adolescents with a higher genetic risk and
that these risks were independent of each other.
Although the absence of an association between a ge-
netic risk for schizophrenia andpsychotic experiences in ado-
lescence may seem surprising, these findings are consistent
with those of previous studies that have examined this
relationship.17,18 The estimates of association and strength of
evidence in this study are very similar to those from a previ-
ous study usingALSPAC,18 although the power in our study is
substantially greater given the use of a much larger training
set to generate the risk-scoring algorithm.
AtPvalue thresholds thatmaximally capture schizophre-
nia liability,psychoticexperiencesweremorecommoninthose
withhigher genetic risk, albeit theCIs included thenull. At the
most stringent P value thresholds, however, we found weak
evidence that genetic risk was associated with reduced psy-
chotic experiences. This finding could be caused by random
error or could result fromattritionbias.Missingdata are likely
greater for thosewhodevelopapsychoticdisorderandfor those
at high genetic risk. Therefore, psychotic experiencesmay be
underrepresented inparticipantswithhighcomparedwith low
genetic risk included in these analyses, akin to the appar-
ently protective effect of smoking on Alzheimer disease risk
seenusing risk rather than ratemodels of analysis.31Why this
wouldonly beobserved atPvalue thresholds that explain less
of the variance for schizophrenia is not clear.
Table 2. Effects of Schizophrenia PRS on Psychopathological Outcomes and Comparison of Specific vs Common Effecta
Phenotype 1 Phenotype 2
No. of
Participants
Effect, OR (95% CI)
P Valueb
Phenotype Specific
Common1 2
Psychotic experiences Negative symptoms 3288 1.04 (0.93-1.15) 1.15 (1.04-1.26) 1.09 (1.02-1.18) .14
Psychotic experiences Depressive disorder 3965 1.06 (0.97-1.16) 1.02 (0.94-1.12) 1.04 (0.97-1.11) .58
Psychotic experiences Anxiety disorder 3966 1.05 (0.96-1.15) 1.16 (1.06-1.26) 1.11 (1.04-1.19) .11
Negative symptoms Depressive disorder 2872 1.17 (1.06-1.30) 0.99 (0.90-1.10) 1.08 (1.00-1.17) .02
Negative symptoms Anxiety disorder 2873 1.17 (1.05-1.30) 1.16 (1.05-1.28) 1.16 (1.08-1.26) .92
Depressive disorder Anxiety disorder 4106 1.01 (0.92-1.10) 1.14 (1.04-1.23) 1.07 (1.00-1.15) .02
Abbreviations: OR, odds ratio; PRS, polygenic risk score.
a Includes complete case data using bivariate model estimation. The ORs are
calculated per SD increase in PRS, with a threshold P = .05 for the discovery
sample.
b Calculated from likelihood ratio tests comparing a model assuming
psychopathologic-specific effect vs a common effect model when the
exposure effect is constrained to be the same across phenotypes. P = .5, for
example, would provide little evidence that the association between the PRS
and phenotype 1 was different from that for the association between the PRS
and phenotype 2. P = .01, for example, would provide strong evidence of a
difference. The eMethods in the Supplement details howORs were derived.
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A number of potential explanations exist for our findings
of strong evidence of an association between genetic risk for
schizophrenia and negative symptoms and anxiety disorder
but not with psychotic experiences in the general popula-
tion.First, genetic risk for schizophreniamaybeexpressedhet-
erotypicallyduringadolescenceasanxietyandnegative symp-
toms, and psychotic experiences may develop later. For the
minorityof individualswho laterdevelopschizophrenia, anxi-
etyandnegative symptomswould representprodromal symp-
toms of the disorder. This possibility implies that, compared
with psychotic experiences arising later in life, hallucina-
tions and paranoid beliefs arising during adolescence might
be explained to a greater degree by nongenetic effects, such
aschildhood trauma32,33 or cannabisuse,34 thanbygenetic risk
for schizophrenia. The association between genetic risk for
schizophrenia andpsychotic experiencesmight therefore be-
come stronger with increasing age akin to that seen for gen-
eral cognitive ability.35
Anxietyandnegativesymptomsmightoccurasearlymani-
festations of genetic risk for schizophrenia, and we might
speculateonpossiblemechanisms.Forexample,disturbedbio-
logical processes secondary to genetic variation might result
in subtle alterations in prediction error processing and attri-
butional salience that might lead to anxiety before the onset
of clear-cutpsychoticphenomena.36,37Genetic risk for schizo-
phrenia is also associated with impaired childhood perfor-
mance IQ in this cohort,38 althoughwe do not knowwhether
variants actingprimarily throughdifferent brainpathways are
differentially related to these phenotypes.
Second, genetic risk for schizophrenia may be expressed
during adolescence as increasedpsychotic experiences, anxi-
ety, and negative symptoms, but psychotic experiences may
be observed with greater measurement error; thus, associa-
tions would be relatively underpowered for this phenotype.
Use of a semistructured interviewand similar estimates using
questionnairessuggest that thisexplanation isunlikelybutcan-
not be excluded.
Third, genetic variants identified as showing an associa-
tion with schizophrenia in the GWASmay only weakly index
the risk for hallucinations and delusions and may reflect ge-
netic riskmore strongly for other characteristics of the disor-
der, such as negative symptoms that index severity or chro-
nicity of illness and that might be selected for in clinically
ascertained samples. Similarly, such ascertainment might be
biased toward those with multiple morbidities, for example,
comorbidanxietydisorders.Studies thathaveexaminedsymp-
tom dimensions within schizophrenia39 and in the general
population40,41 show that the heritability of negative anddis-
organized symptoms is greater than that of positive symp-
toms and that schizophrenia polygenic risk is more strongly
associated with negative and disorganized symptoms than
positive symptoms.42
Althoughevidenceexistsofgeneticoverlapbetweenschizo-
phrenia andmajor depressive disorder in adults,12,43we found
no evidence to support this overlap in our study. Measures of
depression in this studymay capturemore transient disorders
in adolescence that obscure a genetic overlap between schizo-
phrenia and amore persistent, chronic form of depression.
Our results indicate that anxiety and negative symptoms
are likely to be thebestmarkers of highgenetic risk for schizo-
phrenia in population-based samples; however, the variance
of these phenotypes explained by schizophrenia genetic risk
is small (0.5%-0.7%),andthenegativesymptomsmeasureused
in the general population might not fully capture the nega-
tive symptoms seen in schizophrenia. Our findings have po-
tentially important implications for studies of at-risk samples
amongwhomcurrent approaches for informing prediction of
transition rely heavily on psychotic experiences. Our results
are consistent with an evolving literature describing anxiety
as a common symptom during the prodromal stage of
psychosis.44-46
Our study has a number of strengths. First, we used the
most recent schizophrenia GWAS from the PGC1—the largest
schizophrenia data set available—as a training set, thusmini-
mizing measurement error. Second, we used a large, well-
characterized, relatively homogeneous, population-based
sample for examining psychosis-related phenotypes during
adolescence, a key period of development that closely pre-
dates the start of thepeak in incidenceof schizophrenia.Third,
we used a semistructured interview to determine the pres-
enceof psychotic experiences, as used clinically.Wealsoused
multiplemeasures of depression andanxiety at different ages
during adolescence anddifferent cutoffs of these andofmea-
suresofpsychotic experiences andnegative symptomsas sen-
sitivity analyses to test the robustness of our findings.
Our study also has a number of limitations. First, despite
the use of one of the largest population-based birth cohorts
worldwidewith the required data, our samplemay not be ad-
equately powered to identify small effects of cumulative ge-
netic risk on thephenotypes examined,19 especially givenpo-
tential differences inheritability across thephenotypes.14,40,41
Given that our sample is too small to estimate heritability of
the phenotypes accurately, determining whether the ab-
senceof evidenceof associationbetweenaphenotype andge-
netic risk for schizophrenia reflects an absence of genetic cor-
relationor inadequatepower is difficult. Second,missingdata
in the cohort could lead to bias in our estimates. Genetic risk
for schizophrenia47 and presence of mental health problems
are associatedwith reduced retention in cohort studies,which
would tend to underestimate associations. Although selec-
tive missingness may have led to overestimates of associa-
tion, this possibility seems unlikely for some of our pheno-
types but not others. A further limitation is that rare genetic
variants are not captured by a GWAS; therefore, we are only
able to examine the effect of common variants (as captured
by the current GWAS) on adolescent phenotype expression.
Conclusions
Our results highlight the need for GWAS consortia of schizo-
phrenia to includedetailed phenotypingdata, to examine the
extent towhich current GWAS findings relate to specific phe-
notypes, and to identifygeneticvariants andpathways that are
symptom-domain specific rather than to examine the pres-
ence of disorder per se. Furthermore, large population-based
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longitudinal studies with robust measures of these pheno-
typic constructs are required todeterminehowgenetic risk for
schizophrenia is expressed from childhood through adult-
hood andwhether this expression changeswith age, to exam-
ine potential mediators andmoderators of risk, and to deter-
mine the usefulness of genetic risk scores for prediction of
transition to psychosis. A better understanding of how ge-
netic risk for schizophrenia manifests during development
could inform early recognition of problems in those at great-
est risk and potentially inform targeted interventions.
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